SAB Biotherapeutics, Inc. (SABS)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
SABS price, last 12 months
Key stats
- Previous close
- $3.35
- Open
- $3.36
- Day range
- $3.27 – $3.49
- 52-week range
- $1.85 – $5.15
- Volume
- 2.4M
- Avg volume (20 days)
- 519.6K
- Market cap
- $299.3M
Performance
Technicals and fundamentals
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $299.3M